According to Pfizer CEO Albert Bourla, annual vaccination against coronavirus may be needed, and more often for high-risk patients. The adapted Omicron vaccine should be available in March.
EMA to make decision on anti-corona pill
According to Pfizer CEO Albert Bourla, annual vaccinations against coronavirus may become necessary. High-risk patients may need even more frequent boosters, he said at a J.P. Morgan health care conference Monday. Bourla reiterated the announcement that a special vaccine from BioNTech’s partner against Omikron would be ready in March.
He told CNBC a few hours before the event that testing was still needed to determine whether a fourth vaccination would be necessary initially.
Omicron vaccination still in March
BioNTech reiterated that a vaccine adapted to the Omicron variant of the coronavirus could be available as early as March. Overall, the company continues to target production capacity of up to four billion vaccine doses this year.
BioNTech expects to make up to 17 billion euros from corona vaccine this year
German pharmaceutical company BioNTech expects sales of up to 17 billion euros this year from its Covid-19 vaccine alone. Last year, sales are likely to have been 16 to 17 billion euros, as previously predicted. In 2022, CEO Ugur Sahin expects a range of 13 billion to 17 billion euros, according to an investor presentation released Tuesday.
source: APA/picture: pixabay.com
This post has already been read 46 times!